MaxCyte (NASDAQ:MXCT) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

MaxCyte (NASDAQ:MXCT) issued its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01, FiscalAI reports. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. The firm had revenue of $6.50 million for the quarter, compared to analyst estimates of $6.51 million.

Here are the key takeaways from MaxCyte’s conference call:

• MaxCyte reiterated its 2026 revenue guidance of $30 million–$32 million, with low single-digit year-over-year growth expected in the second half as instrument placements recover and prior inventory and partner-program headwinds subside.
• The new enterprise-level Genentech partnership provides access to MaxCyte’s ExPERT GTx, electroporation, and SeQure technologies across multiple programs and development stages, potentially creating recurring license, platform-use, instrument, consumables, and milestone revenue.
• Commercial momentum for Vertex’s CASGEVY continued, with approximately $76 million in second-quarter sales and more than 100 patient treatment initiations; MaxCyte’s SPL-related revenue rose to $0.8 million from $0.3 million a year earlier.
• Management reported broad stabilization in instrument and processing-assembly demand, early traction for the DTx platform, and expects instrument revenue to be the primary growth driver in the second half; it also sees potential commercial launches from five partner programs over the next few years, mainly in 2027.
• Second-quarter revenue declined 15% year over year to $7.3 million, while core revenue fell 21%; gross margin also decreased to 77% from 82% and is expected to remain in the mid-70% range as instrument revenue represents a larger mix.

MaxCyte Stock Up 18.3%

MXCT stock opened at $1.50 on Thursday. The business has a 50 day moving average price of $1.19 and a 200 day moving average price of $0.98. The stock has a market cap of $160.89 million, a price-to-earnings ratio of -4.04 and a beta of 1.48. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $1.86.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MXCT. Weiss Ratings downgraded shares of MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in shares of MaxCyte during the second quarter worth approximately $26,000. State of Wyoming purchased a new position in MaxCyte during the 2nd quarter worth $38,000. BNP Paribas Financial Markets increased its stake in MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after purchasing an additional 18,913 shares during the period. Jain Global LLC acquired a new position in MaxCyte in the fourth quarter valued at $45,000. Finally, Virtu Financial LLC acquired a new stake in shares of MaxCyte during the fourth quarter worth about $67,000. Hedge funds and other institutional investors own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.